AU Patent

AU2025200220A1 — Improved lyophilized formulation

Assigned to Stemline Therapeutics Inc · Expires 2025-01-30 · 1y expired

What this patent protects

Provided herein are improved formulations of tagraxofusp for lyophilization used to manufacture stable formulations of tagraxofusp for intravenous injection.

USPTO Abstract

Provided herein are improved formulations of tagraxofusp for lyophilization used to manufacture stable formulations of tagraxofusp for intravenous injection.

Drugs covered by this patent

Patent Metadata

Patent number
AU2025200220A1
Jurisdiction
AU
Classification
—
Expires
2025-01-30
Drug substance claim
No
Drug product claim
No
Assignee
Stemline Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.